Background: Systemic sclerosis, often known as scleroderma, is a rare connective tissue illness whose cause is uncertain and complex. Scleroderma is classified into two types: localised scleroderma (including morphea, linear scleroderma, and scleroderma en coup de sabre) and systemic sclerosis. Based on clinical and serological criteria, systemic sclerosis can be defined as limited systemic sclerosis (previously known as CREST syndrome, which includes calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) or diffuse systemic sclerosis. Localised scleroderma primarily affects the skin and subcutaneous tissue, whereas systemic sclerosis has systemic symptoms and involves internal organs, which increases mortality. Scleroderma symptoms can closely resemble those of other rheumatological or immunological illnesses. The harshness of the presentation can also change based on the timing.